Timing clarification: DaVita is scheduled to release results after the market closes today, Tuesday, August 4, 2026, followed by its conference call at 5:00 p.m. ET—not tomorrow. (newsroom.davita.com)
DaVita enters the quarter with strong operating momentum—and a substantially higher valuation. The central question is no longer whether the business is improving, but whether treatment growth, labor productivity and share repurchases can support another guidance increase.
The most important indicators will be:
A modest EPS beat may not be enough after the stock’s sharp post-Q1 appreciation. Investors will probably focus more on full-year guidance and the quality of the operating performance than on the headline quarterly result.
| Metric | Q2 2026 expectation | Q2 2025 actual |
|---|---|---|
| Revenue | $3.50 billion | $3.38 billion |
| Adjusted diluted EPS | $3.88 | $2.95 |
| Implied growth | Revenue: ~4% | — |
| Adjusted EPS: ~32% | — |
Current published consensus is approximately $3.88 of adjusted EPS on $3.50 billion of revenue. (tipranks.com)
The large expected EPS increase is likely to come from a combination of operating-income growth and a sharply lower share count—not comparable revenue growth alone.
DaVita’s first quarter was better than management had anticipated:
Management raised 2026 guidance to:
It also raised expected full-year treatment growth to 25-50 basis points, citing better underlying census performance and patient transfers associated with competitor clinic closures. (investors.davita.com)
Volume is the cleanest fundamental marker this quarter.
In Q1, average treatments per normalized day rose 0.4% year over year, while normalized non-acquired growth was only 0.1%. Management nevertheless expected growth to improve through the year because:
The market will want to see normalized treatment growth move clearly above Q1’s 0.1%, along with confirmation that the transfer gains are durable rather than merely shifting quarterly timing.
Bullish: Treatment growth accelerates toward or above the upper half of the annual range, with stable admissions and mortality.
Bearish: Transfers underperform, new dialysis starts remain weak or management retreats from its 25-50 basis-point treatment-growth outlook.
Q1 revenue per treatment was unusually strong at $417.59, but management attributed roughly $6 of the year-over-year increase to timing and retained its full-year RPT growth forecast of only 1%-2%.
Q2 should benefit sequentially from patients satisfying deductibles and coinsurance. The more important issue is what happens after adjusting for that seasonality.
Management previously estimated an approximately $40 million 2026 headwind from ACA-plan dynamics. Q1 enrollment was slightly better than anticipated, but more patients selected lower-premium bronze plans, increasing patient-pay exposure. Commercial mix and Medicare Advantage penetration were broadly stable in Q1.
Investors should watch for:
A strong headline RPT figure will be less meaningful if it reflects timing rather than sustainable reimbursement or mix.
Q1 patient-care costs were better than management expected, largely because of productivity improvements. This was one of the main reasons DaVita raised its operating-income guidance.
The critical question is whether these efficiencies continued through Q2 despite wage inflation, insurance costs and an industry-wide shortage of skilled clinical labor.
DaVita is also spending more on technology. U.S. dialysis G&A rose 13% year over year in Q1, primarily because of IT investments. Management argues that investors should evaluate total costs rather than G&A in isolation, because technology may lower center-level labor and administrative costs elsewhere.
A high-quality quarter would therefore show:
The danger is that Q1’s productivity benefit was partly timing-related and that wage or benefit costs reaccelerate.
Integrated Kidney Care recorded a $19 million operating loss in Q1, compared with a $46 million profit in Q4 2025. Management said the variation reflected shared-savings timing and expects IKC income to be weighted toward Q4.
Consequently, Q2 IKC results could remain weak without necessarily implying deterioration in the full-year outlook. Investors should focus on:
Still, another loss paired with softer full-year commentary would raise questions about the predictability and economic value of the business.
DaVita repurchased:
The company had approximately 64.2 million shares outstanding on May 5, down substantially from the prior year. (sec.gov)
That lower denominator is a major contributor to the expected EPS growth. However, it comes with a balance-sheet trade-off:
The report should reveal whether DaVita kept repurchasing aggressively as the share price rose. Buybacks made sense at the roughly $134-$150 prices paid early in the year; the return is less obvious with the stock above $230.
Management said after Q1 that adjusted operating income should be approximately evenly distributed across the final three quarters of 2026.
After subtracting Q1’s $482 million from the full-year range, that implies approximately:
That is a useful operating-income benchmark for Q2.
The existing EPS range has a midpoint of $14.65. At the August 3 closing price of $233.72, DVA traded at roughly 16x midpoint 2026 adjusted EPS guidance. The stock also had risen approximately 49% from its May 5 close, meaning expectations have increased considerably since the Q1 report.
This would support the view that DaVita can produce attractive per-share earnings growth even with modest underlying treatment volumes.
That would be a solid fundamental report, although the stock reaction could be muted given its recent performance.
DaVita’s setup is fundamentally favorable: treatment trends have improved, labor productivity is supporting margins and aggressive repurchases are driving substantial EPS accretion. But much of that optimism is now reflected in the share price.
The most important result will not be whether adjusted EPS exceeds $3.88. It will be whether management can demonstrate that the volume and productivity improvements behind Q1 are sustainable—and translate them into higher full-year guidance without taking leverage beyond its preferred range.